Skip to main
PRVA

PRVA Stock Forecast & Price Target

PRVA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 71%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Privia Health Group Inc. has demonstrated robust growth in provider additions, achieving the bull case of onboarding 125 providers in the fourth quarter of 2025, which positions the company for continued scalability. Financial projections for fee-for-service practice collections per provider show an upward trend, with a sequential increase of approximately 9% in the third quarter of 2025, bolstered by strong performance in the Arizona market and improvements in operational efficiency. The company's strategic initiatives in reducing administrative burdens for physicians and expanding its value-based care portfolio contribute to enhanced profitability and sustained revenue growth prospects.

Bears say

Privia Health Group Inc is facing a grim outlook due to anticipated declines in Medicaid enrollment, with an expected reduction of 8%-10% in membership by year-end, which is attributed to re-determination activities following the public health emergency. This scenario is further compounded by projections of a sequential decline in EBITDA after a strong performance in Q3, indicating potential challenges in maintaining profitability. Additionally, the company's expectations of a 2% quarter-over-quarter decrease in same-store metrics—despite typical seasonality trends predicting an increase—underscore ongoing operational difficulties that may negatively impact its financial stability.

PRVA has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 71% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Privia Health Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Privia Health Group (PRVA) Forecast

Analysts have given PRVA a Buy based on their latest research and market trends.

According to 14 analysts, PRVA has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Privia Health Group (PRVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.